SynCore BiotechnologyLtd (4192) Stock Overview
Engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4192 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SynCore Biotechnology Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$24.90 |
| 52 Week High | NT$38.50 |
| 52 Week Low | NT$24.00 |
| Beta | 0.34 |
| 1 Month Change | -4.05% |
| 3 Month Change | -7.43% |
| 1 Year Change | -27.93% |
| 3 Year Change | -73.91% |
| 5 Year Change | -85.12% |
| Change since IPO | -94.31% |
Recent News & Updates
Shareholder Returns
| 4192 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.8% | -1.5% | 2.8% |
| 1Y | -27.9% | 16.5% | 27.0% |
Return vs Industry: 4192 underperformed the TW Pharmaceuticals industry which returned 16.5% over the past year.
Return vs Market: 4192 underperformed the TW Market which returned 27% over the past year.
Price Volatility
| 4192 volatility | |
|---|---|
| 4192 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 4192 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4192's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Muh-Hwan Su | www.syncorebio.com |
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials.
SynCore Biotechnology Co.,Ltd Fundamentals Summary
| 4192 fundamental statistics | |
|---|---|
| Market cap | NT$875.61m |
| Earnings (TTM) | -NT$46.41m |
| Revenue (TTM) | NT$26.26m |
Is 4192 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4192 income statement (TTM) | |
|---|---|
| Revenue | NT$26.26m |
| Cost of Revenue | NT$7.17m |
| Gross Profit | NT$19.09m |
| Other Expenses | NT$65.50m |
| Earnings | -NT$46.41m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32 |
| Gross Margin | 72.69% |
| Net Profit Margin | -176.76% |
| Debt/Equity Ratio | 0% |
How did 4192 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/03 23:41 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SynCore Biotechnology Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.